Research Use Only. The information presented here is for scientific and educational purposes. These compounds are not intended for human consumption, self-administration, or therapeutic use.
Introduction
The pituitary somatotroph sits at the center of the growth hormone (GH) axis, and its output is governed by more than one incoming signal, which is the crux of the GHS vs GHRH comparison. Two families of research peptides are studied for their ability to prompt GH release, yet they engage the somatotroph through entirely separate receptors. Growth hormone-releasing hormone (GHRH) analogs act on the GHRH receptor, while growth hormone secretagogues (GHS), also called growth hormone-releasing peptides (GHRPs), act on the ghrelin receptor. Understanding where each class binds is the key to understanding why they behave so differently in preclinical models.
This GHS vs GHRH overview contrasts the two mechanisms and places representative compounds on each side of the divide. On the GHRH side sit Sermorelin and CJC-1295; on the secretagogue side sit Ipamorelin and GHRP-2. All discussion below is framed around what these peptides are investigated for in laboratory and animal research; the material is for research use only, not for human consumption.
Two Receptors, Two Signals: The GHS vs GHRH Distinction
The mechanistic split between the two classes comes down to which receptor is activated and which intracellular cascade follows. Both routes converge on GH release, but they arrive there by different molecular roads.
The GHRH receptor pathway
GHRH analogs bind the GHRH receptor (GHRHR), a class B G-protein-coupled receptor expressed on somatotrophs. Receptor activation couples to the stimulatory G protein (Gs), raising intracellular cyclic AMP (cAMP) and activating protein kinase A (PKA). In research models this cascade is associated with both the synthesis of new GH and the release of stored hormone. The endogenous ligand is GHRH, a 44-amino-acid hypothalamic peptide whose first 29 residues carry most of the biological activity, which is why the fragment GHRH(1-29) serves as the template for sermorelin.
The ghrelin receptor pathway
Growth hormone secretagogues bind the GHS receptor (GHSR-1a), the same class A receptor targeted by the gut hormone ghrelin. Here the coupling runs through Gq, activating phospholipase C and raising intracellular calcium through the IP3 and DAG arm. A second, distinct feature of this pathway is that GHS signaling reduces the inhibitory tone of somatostatin, the hormone that normally applies the brakes to GH output. Put simply, GHRH analogs press one accelerator, while secretagogues press a different accelerator and ease off the brake at the same time.
The values in the table below reflect commonly reported laboratory attributes and are provided for comparison only.
| Attribute | GHRH Analogs | Growth Hormone Secretagogues (GHS/GHRP) |
|---|---|---|
| Primary receptor | GHRH receptor (GHRHR) | GHS receptor (GHSR-1a, ghrelin receptor) |
| Receptor class | Class B GPCR | Class A GPCR |
| Endogenous ligand | GHRH (hypothalamic, 44 aa) | Ghrelin (gastric, 28 aa) |
| Main signaling arm | Gs, cAMP, PKA | Gq, phospholipase C, calcium |
| Effect on somatostatin | Little direct effect | Reduces somatostatin tone |
| Representative peptides | Sermorelin, CJC-1295, Tesamorelin | Ipamorelin, GHRP-2, GHRP-6 |
| Typical peptide size | Larger (29-44 residues) | Small (5-6 residues) |
GHRH Analogs: Sermorelin, CJC-1295, and Tesamorelin
The GHRH family is defined by structural kinship to native GHRH and by a shared reliance on the GHRH receptor. A recurring theme in the research literature is that these analogs tend to amplify the natural, pulsatile pattern of GH release rather than override it, because the somatotroph and its somatostatin brake remain in control of timing.
Sermorelin and the GHRH(1-29) template
Sermorelin is the acetate salt of GHRH(1-29), the shortest fragment that retains full GHRH-like activity in research settings. Because it is a close copy of the native sequence, it is frequently used as the reference GHRH analog. Its relatively short duration of action in models mirrors the brief half-life of endogenous GHRH.
CJC-1295 and half-life engineering
CJC-1295 is a modified GHRH(1-29) carrying several amino acid substitutions that resist enzymatic breakdown. The version described in the literature with a Drug Affinity Complex (DAC) adds a linker that binds circulating albumin, greatly extending the peptide’s residence time in animal studies. The variant without DAC, often labeled modified GRF(1-29), is shorter acting. Both are studied for how sustained GHRH-receptor stimulation reshapes the GH profile over time.
Tesamorelin
Tesamorelin is a stabilized analog of full-length GHRH(1-44) modified with a trans-3-hexenoic acid group. It is the largest of the common GHRH analogs and is investigated as another route to durable GHRH-receptor activation.
Growth Hormone Secretagogues: Ipamorelin and GHRP-2
The secretagogue family is structurally unrelated to GHRH. These are small peptides modeled on the activity of ghrelin at the GHS receptor, and their compact size is itself a distinguishing feature.
Ipamorelin
Ipamorelin is a selective pentapeptide (five residues) and one of the most studied GHRPs precisely because of its selectivity. In preclinical work it is noted for stimulating GH release through the ghrelin receptor with minimal reported effect on cortisol and prolactin, which distinguishes it from earlier, less selective secretagogues.
GHRP-2
GHRP-2, also known as pralmorelin, is a hexapeptide (six residues) and a potent GHS receptor agonist. Compared with ipamorelin, the research literature notes that GHRP-2 and its relative GHRP-6 can also influence other pituitary outputs, which is one reason selectivity is a frequent point of comparison among secretagogues.
Peptide and non-peptide secretagogues
Not every secretagogue is a peptide. Small-molecule GHS receptor agonists exist as well, but the peptide GHRPs remain the most commonly referenced compounds in comparative research on the ghrelin pathway.
The identity values below reflect commonly reported laboratory attributes and are provided for comparison only.
| Compound | Class | Sequence length | Approx. molecular weight |
|---|---|---|---|
| Ipamorelin | GHS / ghrelin agonist | 5 residues | ~712 Da |
| GHRP-2 | GHS / ghrelin agonist | 6 residues | ~818 Da |
| Sermorelin | GHRH analog | 29 residues | ~3358 Da |
| CJC-1295 (with DAC) | GHRH analog | 29 residues plus DAC | ~3647 Da |
| Tesamorelin | GHRH analog | 44 residues | ~5136 Da |
Why the Two Classes Are Studied Together
Because GHRH analogs and secretagogues act on separate receptors and separate signaling arms, a central research question is what happens when both are activated at once. The two inputs are complementary rather than redundant.
In multiple preclinical and physiological studies, combined GHRH-receptor and GHS-receptor stimulation produces a larger GH response than either input alone, a genuine synergy rather than simple addition. The interpretation is mechanistic: GHRH raises cAMP inside the somatotroph while the secretagogue simultaneously raises calcium and lifts the somatostatin brake, so the two signals reinforce one another. This is the rationale behind studying paired combinations such as the CJC-1295 and Ipamorelin blend, where a long-acting GHRH analog is examined alongside a selective secretagogue.
For a research program, the GHS vs GHRH choice, or the decision to combine them, follows from the mechanism under investigation. A study focused on cAMP-driven somatotroph biology points toward a GHRH analog, whereas one focused on ghrelin-receptor pharmacology or somatostatin withdrawal points toward a secretagogue. Whichever direction the work takes, sourcing matters: verifying identity and purity through a certificate of analysis is a baseline step, and the full catalog of research peptides lists the specific compounds referenced here.
Frequently Asked Questions
What is the difference between a growth hormone secretagogue and a GHRH analog?
The difference is the receptor. A GHRH analog activates the GHRH receptor on pituitary somatotrophs through the cAMP pathway, whereas a growth hormone secretagogue activates the ghrelin receptor (GHSR-1a) through the calcium pathway and also reduces somatostatin tone. Both raise GH release in research models, but by separate mechanisms.
Is ipamorelin a GHRH analog or a secretagogue?
Ipamorelin is a growth hormone secretagogue, specifically a selective pentapeptide GHRP that acts on the ghrelin receptor. It is not structurally related to GHRH and does not bind the GHRH receptor.
What receptor does CJC-1295 target?
CJC-1295 targets the GHRH receptor. It is a modified GHRH(1-29) analog, so it belongs to the GHRH-analog class rather than the secretagogue class, and it signals through the Gs and cAMP pathway.
Why are CJC-1295 and ipamorelin often studied together?
Because they act on different receptors and complementary signaling arms, combining a GHRH analog such as CJC-1295 with a secretagogue such as ipamorelin produces a greater GH response in research models than either compound alone. The pairing is a common way to study receptor synergy at the somatotroph.
Does GHRP-2 work the same way as sermorelin?
No. GHRP-2 is a secretagogue that binds the ghrelin receptor, while sermorelin is a GHRH analog that binds the GHRH receptor. They converge on the same outcome, GH release, but through distinct receptors and second messengers.
Are growth hormone secretagogues the same as ghrelin?
They are not identical, but they share a target. Ghrelin is the endogenous ligand of the GHS receptor, and secretagogues such as ipamorelin and GHRP-2 are synthetic peptides designed to activate that same receptor, which is why the GHS receptor is also called the ghrelin receptor.
References and Further Reading
- Bowers CY and colleagues, foundational work on growth hormone-releasing peptides and their receptors. PubMed: growth hormone releasing peptide Bowers
- Kojima and Kangawa, discovery of ghrelin as the endogenous GHS-receptor ligand. PubMed: ghrelin growth hormone secretagogue receptor
- Structure and signaling of the GHRH receptor on somatotrophs. PubMed: GHRH receptor signaling somatotroph
- Ipamorelin selectivity and pituitary hormone specificity in preclinical research. PubMed: ipamorelin growth hormone
- CJC-1295 and albumin-binding, long-acting GHRH analog pharmacology. PubMed: CJC-1295 GHRH analog
- Sermorelin and GHRH(1-29) as a reference growth hormone-releasing analog. PubMed: sermorelin GHRH 1-29
- Synergy of GHRH and GHRP co-administration on growth hormone release. PubMed: GHRH GHRP synergy growth hormone
